• About us
• Contact

Advertisement

Organisation › Details

Compass Pathways plc (Nasdaq: CMPS)

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. *

 

	Start	2020-08-01 renamed
	Group	Compass Pathways (Group)
	Predecessor	Compass Rx Ltd.
	Industry	psilocybin
	Person	Goldsmith, George (Compass Pathways 202004 CEO + Co-Founder)
	Person 2	Wilde, Lars Christian (Compass Pathways 202004 CBO + Co-Founder)
	Region	Altrincham, Greater Manchester
	Country	United Kingdom (GB)
	Street	1 Ashley Road 3rd Floor
	City	WA14 2DT Altrincham, Cheshire
		Address record changed: 2020-12-02
Basic data	Employees	C: 51 to 100 (2020-12-31)
	Currency	USD
	Profit	-60,334,000 (2020-12-31)
	Cash	190,327,000 (2020-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Compass Pathways (Group)

• [1] Consilium Strategic Communications Ltd.. (5/6/22). "Press Release: Consilium Strategic Communications Appoints Tracy Cheung as Partner". London....
• [2] Compass Pathways plc. (9/14/21). "Press Release: Compass Pathways Acquires IP Portfolio of Novel Psychedelic Compounds and Prodrugs". London....
• [3] Compass Pathways plc. (7/5/21). "Press Release: Compass Pathways Joins Forces with King’s College London and South London and Maudsley NHS Foundation Trust to Accelerate Psychedelic Research and Develop New Models of Mental Health Care in the UK". Londo...
• [4] Compass Pathways plc. (4/30/21). "Press Release: Compass Pathways Announces Pricing of Public Offering". London....
• [5] Compass Pathways plc. (4/27/21). "Press Release: Compass Pathways Launches Proposed Public Offering". London....
• [6] Quercis Pharma AG. (4/13/21). "Press Release: Quercis Announces Executive Leadership Appointments". Zug....
• [7] Consilium Strategic Communications Ltd.. (10/15/20). "Press Release: Consilium Strategic Communications Advises Compass Pathways on Its Successful Initial Public Offering". London....
• [8] Compass Pathways plc. (9/22/20). "Press Release: Compass Pathways Announces Closing of Initial Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase additional American Depositary Shares". London....
• [9] Compass Pathways plc. (9/18/20). "Press Release: Compass Pathways Announces Pricing of Upsized Initial Public Offering". London....
• [10] Compass Pathways Ltd.. (4/27/20). "Press Release: Mental Health Care Company Compass Pathways Concludes Successful Series B Investment Round. $80m Raised Will Further the Development of Psilocybin Therapy". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.